Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the International AIDS Society"
DOI: 10.1002/jia2.25862
Abstract: Efavirenz (EFV) is commonly used for first‐line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV… read more here.
Keywords: virologically suppressed; suppressed adolescents; switching efavirenz; week ... See more keywords